tracken
Tvardi Therapeutics Aktie News
Neutral
PRNewsWire
●
etwa 12 Stunden alt
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may ...
Neutral
GlobeNewsWire
●
ein Tag alt
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options
Neutral
PRNewsWire
●
5 Tage alt
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may ...
Neutral
GlobeNewsWire
●
6 Tage alt
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options
Neutral
PRNewsWire
●
13 Tage alt
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may ...
Neutral
GlobeNewsWire
●
14 Tage alt
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Tvardi To Contact Him Directly To Discuss Their Options
Neutral
Business Wire
●
17 Tage alt
HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the company's management will participate in a fireside chat and host investor one-on-one investor meeti...
Neutral
PRNewsWire
●
20 Tage alt
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Tvardi To Contact Him Directly To Discuss Their Options If you suffered losses in Tvardi and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
